Vaccine publishes independent survey showing overwhelming preference for Needle-free technology in large-scale intradermal polio vaccination campaignThe campaign, sponsored by the World Health Organization as part of its polio eradication efforts, vaccinated 500,000 children, aged 4 – 59 months, over a one-week period in early 2019. Data on acceptability of the PharmaJet Tropis Needle-Free Injection System was collected from 610 vaccinators and 4,898 caregivers. Of those with prior needle and syringe… Details
Study published in Clinical Cancer Research cites important progress towards new treatments for cancer using PharmaJet TropisInvectys published the results of their Phase I clinical trial testing their immune-therapeutic DNA cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system (Teixeira et al, 2019). The publication cites that “administration with the PharmaJet Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients. Details
Clinical Study published in The Lancet shows significantly higher immune response with Needle-free injectionThe Lancet recently published a study that demonstrates that the delivery of a Zika virus vaccine with the PharmaJet Stratis Needle-free Jet injector resulted in a higher immune response as compared with administration via needle and syringe. Details
Study published in Heliyon Journal shows superiority of needle-free injection over needle and syringe for poliovirus vaccine fIPV campaignsAdministration of intradermal fractional dose of inactivated poliovirus vaccine (fIPV) has proven to be safe and immunogenic; however, intradermal injection using needle and syringe is technically difficult and requires trained personnel. Details
Clinical study published in Vaccine cites superiority of two fractional doses administered intradermally to one full intramuscular dose. Expands use of PharmaJet Tropis Needle-free InjectorThe polio eradication endgame strategic plan calls for the sequential removal of Sabin poliovirus serotypes from the trivalent oral poliovirus vaccine (tOPV), starting with type 2, and the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV), to maintain an immunity base against poliovirus type 2. Details
ONdrug DELIVERY publishes PharmaJet Study that links Needle-free Injection to Increasing Workplace Flu Shot ComplianceONdrugDELIVERY publishes PharmaJet Study Offering needle-free technology in a workplace influenza immunization program has the potential to help address an unmet need for increasing workplace health immunization rates. Details
IMPORTANT SAFETY INFORMATION FOR CONSUMERS
What is Afluria®, Influenza Vaccine?
Afluria is an inactivated (virus is not alive) influenza vaccine used for immunization against influenza disease caused by influenza virus subtypes A and B present in the vaccine.